Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21328480 | 0.78 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL26849587 | 0.75 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL4810703 | 0.74 | DGAT1 (0.42) | DGAT1METAP1 | |
| SCHEMBL2317816 | 0.73 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL1771115 | 0.73 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL23294586 | 0.72 | GABRG2 (0.40) | DGAT1 | |
| SCHEMBL29852224 | 0.72 | GABRG2 (0.40) | DGAT1 | |
| SCHEMBL25897621 | 0.71 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL31111573 | 0.69 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL2546186 | 0.68 | BMPR1A (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | DGAT1 3033/4885METAP1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.